Neurocore: Taking On Depression One Person at a Time


Neurocore is a company that was founded in 2004. It is a company that is committed to the health and well being of the brains of children and adults. The company uses brain-based assessments in order to find the proper course of treatment for the patient. Neurocore helps people and children with anxiety disorders, ADHD which means Attention Deficit Hyperactivity Disorder, and most of all depression. Read more about Neurocore at muscletech.com.

Neurocore has eight branches located in Michigan and Florida. The experience at Neoucore is simple. First, a person takes a series of brain analysis tests. Secondly, the staff at Neurocore can devise a program for the patient. Finally, the staff at Neurocore help the patient deal with the problem and ensure positive results. One of the main goals of Neurocore is to help people deals with depression. Here are a few facts about depression that may make a person take a harder look at the disease.

The first fact is that depression can occur without any outside influence. There are many factors that can contribute to depression but there is no one concrete cause for the disease. People who been through rough times or have a family history are more likely to have the disease than those who do not. Follow Neurocore on twitter.com.

Another fact about depression is that it takes a physical toll on a person’s body. People with depression can suffer from such things as headaches, stomach ailments, and general tension as well. Brains of those with depression are wired differently from those who are not depressed.

A final fact about depression is that even the most severe cases of depression can be treated with the right care and attention. the fact is that if a person is treated for depression in the earliest stages, it is more likely that the patient will be cured of the disease. This is a fact worth noting.

Neurocore is a company that will always put the patient first. In the cases of depression, Neurocore will take each case on one person at a time. Each case brings Neurocore one step closer to the solution. That is a good thing.

Read: http://www.didyouknow.it/treatment/neurocore-treats-adhd-depression-without-drugs-surgery/

Amicus Therapeutics: Setting New Achievement Levels In The Biopharmaceutical Industry


Amicus Therapeutics is a biopharmaceutical company founded in 2002 based in Cranbury New Jersey and also has a research facility in San Diego. The company uses FOLD as its trading symbol has a global reach with funding partners such as the Alzheimer’s Drug Discovery Foundation and the Michael J. Fox foundation among others. The company focus is on the development of precision medications for devastating, orphan and rare ailments especially those brought about by a genetic mutation. Using CHART-Chaperone advanced replacement Therapy for product development, Amicus Therapeutics has developed enzyme replacement therapies-ERTs products for disorders termed as lysosomal storage disorders.

 

Among the rare diseases that Amicus Therapeutics has developed medicines and technologies for include; Pompe disease, Fabry disease, and Epidermolysis Bullosa. The company goal is to bring a meaningful difference to the lives of the patients with rare and devastating diseases and also to their caregivers. Amicus Therapeutics primary objective is to meet the rare diseases community needs. It has been on the forefront in providing medicines for rare ailments and in 2014 the company was recognized in the pharmaceutical industry as having the largest molecular pharmacological chaperones collection.

 

Migalastat The New Drug For Fabry Disease

Recently, Amicus Therapeutics announced that it has been given the go ahead by FDA to submit migalastat a new precision medication for Fabry’s disease under Subpart H. The submission will be done in the fourth quarter of this year. The medication is an oral drug that can only be administered to teenagers and adults aged 16 years and above. The new drug application will be based on collected data from clinical trials that show that the drug reduces GL-3. GL-3 causes increased morbidity of Fabry’s diseases over time leading to pain, stroke, heart diseases and kidney failure for the patients. Today the number of people suffering from Fabry’s diseases in the US alone is almost 3000 and Amicus Therapeutics believe that this number is big enough for the development of migalastat (WeeklyOpinion). Amicus Therapeutics hopes the drug will be approved soon so that it can change the lives of these patients.

 

Other Achievements

In addition to migalastat their lead product, Amicus Therapeutics have developed other products including SD-101 which is a potential therapy product for Epidermolysis Bullosa a connective genetic disorder. This product is also in its late stages of development. They also have a biologics program ATB200/AT2221 that should be combined with a pharmacological chaperone in its administration. It is for patients suffering from Pompe Disease. In a world where false medication has risen especially for rare diseases. Amicus Therapeutics continues to set new levels of achievements in its specialty and changing the lives of those suffering from devastating and rare diseases.

More about Amicus Therapeutics at https://finance.yahoo.com/quote/FOLD?ltr=1